What’s in INSYS Therapeutics, Inc. (INSY) After Today’s Significant Increase?

April 17, 2018 - By Nellie Frank

Investors sentiment decreased to 0.76 in 2017 Q4. Its down 0.49, from 1.25 in 2017Q3. It worsened, as 21 investors sold INSYS Therapeutics, Inc. shares while 29 reduced holdings. 20 funds opened positions while 18 raised stakes. 16.43 million shares or 9.75% less from 18.21 million shares in 2017Q3 were reported.
D E Shaw And Com stated it has 125,905 shares. State Of Wisconsin Invest Board holds 0% or 19,000 shares. Weiss Multi owns 34,500 shares or 0.01% of their US portfolio. Alliancebernstein Lp accumulated 0% or 74,620 shares. Tiaa Cref Investment Management Lc holds 0% or 62,480 shares in its portfolio. Credit Suisse Ag, a Switzerland-based fund reported 81,928 shares. 35,900 are held by Swiss Retail Bank. Wells Fargo & Mn holds 57,020 shares or 0% of its portfolio. Amer Intl Grp has invested 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Us Retail Bank De owns 75 shares. California Pub Employees Retirement Systems reported 75,500 shares. Fmr Ltd Company invested in 173,684 shares or 0% of the stock. Bessemer Grp Inc invested in 0% or 50 shares. Morgan Stanley invested in 0% or 92,250 shares. Parallax Volatility Advisers Limited Partnership invested in 0% or 3,612 shares.

The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) is a huge mover today! The stock increased 7.81% or $0.49 during the last trading session, reaching $6.76. About 991,955 shares traded or 29.33% up from the average. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 45.03% since April 17, 2017 and is downtrending. It has underperformed by 56.58% the S&P500.
The move comes after 7 months positive chart setup for the $498.65M company. It was reported on Apr, 17 by Barchart.com. We have $7.30 PT which if reached, will make NASDAQ:INSY worth $39.89 million more.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Ratings Coverage

Among 3 analysts covering Insys Therapeutics (NASDAQ:INSY), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. Insys Therapeutics had 4 analyst reports since October 18, 2017 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Wednesday, October 18. The rating was maintained by RBC Capital Markets on Friday, October 27 with “Buy”. The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) has “Underweight” rating given on Friday, March 9 by PiperJaffray. The firm has “Buy” rating by Jefferies given on Friday, November 3.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $498.65 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: